Skip to main content
Addgene

pLKO5d.EFS.SpCas9.P2A.BSD
(Plasmid #57821)

Ordering

This material is available to academics and nonprofits only.
Item Catalog # Description Quantity Price (USD)
Plasmid 57821 Standard format: Plasmid sent in bacteria as agar stab 1 $85

Backbone

  • Vector backbone
    pLKO.005
  • Total vector size (bp) 11054
  • Vector type
    Lentiviral, CRISPR
  • Selectable markers
    Blasticidin

Growth in Bacteria

  • Bacterial Resistance(s)
    Ampicillin, 100 μg/mL
  • Growth Temperature
    37°C
  • Growth Strain(s)
    Stbl3
  • Copy number
    High Copy

Gene/Insert 1

  • Gene/Insert name
    SpCas9
  • Species
    S.pyogenes
  • Insert Size (bp)
    4300
  • Tag / Fusion Protein
    • FLAG (N terminal on insert)

Gene/Insert 2

  • Gene/Insert name
    EFS
  • Species
    H. sapiens (human)
  • Insert Size (bp)
    250
  • Entrez Gene
    EEF1A1 (a.k.a. CCS-3, CCS3, EE1A1, EEF-1, EEF1A, EF-Tu, EF1A, EF1A1, EF1alpha1, GRAF-1EF, LENG7, PTI1, eEF1A-1)

Gene/Insert 3

  • Gene/Insert name
    P2A-BSD
  • Alt name
    Blasticidin resistance
  • Species
    Synthetic
  • Insert Size (bp)
    600

Resource Information

Terms and Licenses

  • Academic/Nonprofit Terms
  • Industry Terms
    • Not Available to Industry
Trademarks:
  • Zeocin® is an InvivoGen trademark.
How to cite this plasmid ( Back to top)

These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.

  • For your Materials & Methods section:

    pLKO5d.EFS.SpCas9.P2A.BSD was a gift from Benjamin Ebert (Addgene plasmid # 57821 ; http://n2t.net/addgene:57821 ; RRID:Addgene_57821)
  • For your References section:

    Generation of mouse models of myeloid malignancy with combinatorial genetic lesions using CRISPR-Cas9 genome editing. Heckl D, Kowalczyk MS, Yudovich D, Belizaire R, Puram RV, McConkey ME, Thielke A, Aster JC, Regev A, Ebert BL. Nat Biotechnol. 2014 Jun 22. doi: 10.1038/nbt.2951. 10.1038/nbt.2951 PubMed 24952903